Jun 2, 2026 07:30AM
Jun 2, 2026 07:30AM
Apr 15, 2026 08:00AM
Apr 13, 2026 05:05PM
Nov 18, 2025 04:15PM
Oct 7, 2025 08:30AM
Oct 2, 2025 08:30AM Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
Oct 1, 2025 09:21AM
Sep 11, 2025 08:00AM
Jul 9, 2025 08:00AM
Jul 9, 2025 08:00AM
Nov 10, 2023 07:01AM
Nov 1, 2023 07:01AM
Oct 23, 2023 07:01AM KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
Oct 11, 2023 07:01AM
Oct 5, 2023 07:01AM
Sep 29, 2023 07:01AM
Jul 6, 2023 07:00AM
Jun 8, 2023 07:00AM
May 25, 2023 07:01AM
Apr 14, 2023 07:02AM Kazia (KZIA) Regains Compliance With Nasdaq Minimum Bid Price Requirement
Apr 14, 2023 07:01AM
Apr 4, 2023 07:00AM
Dec 15, 2022 07:01AM
Dec 12, 2022 07:01AM
Dec 1, 2022 07:01AM
Nov 9, 2022 07:00AM
Oct 27, 2022 07:00AM KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA
Oct 6, 2022 08:00AM
Sep 9, 2022 08:00AM
Sep 8, 2022 08:30AM
Aug 5, 2022 08:40AM
Jul 12, 2022 08:15AM
Jul 6, 2022 07:00AM
Jun 17, 2022 08:00AM US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Jun 13, 2022 07:00AM
Jun 7, 2022 07:00AM
Jun 3, 2022 07:00AM
May 31, 2022 07:00AM
May 23, 2022 08:30AM
May 17, 2022 08:00AM
Apr 29, 2022 11:00AM KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
Apr 8, 2022 08:30AM
Apr 8, 2022 08:00AM
Mar 21, 2022 08:00AM
Feb 28, 2022 08:00AM
Feb 7, 2022 08:00AM
Jan 25, 2022 08:00AM
Jan 7, 2022 08:00AM KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
Dec 13, 2021 11:00AM

322,967 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All